Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

62.07 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
From Pomerantz LLP
Via GlobeNewswire
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Tempus Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tempus AI, Inc. - TEM
From Pomerantz LLP
Via GlobeNewswire
TEM Investor News: If You Have Suffered Losses in Tempus AI, Inc. (NASDAQ: TEM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
From Tempus AI, Inc.
Via Business Wire
Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Real-World Deployments Signal AI Healthcare Is Ready for Scale
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:BTAI),(OTCPK:HWAIF),(OTCQX:WHTCF) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
From Gibbs Mura
Via Business Wire
TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation – TEM
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Tempus AI, Inc. – TEM
From Pomerantz LLP
Via GlobeNewswire
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
From Tempus AI, Inc.
Via Business Wire
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
From Tempus AI, Inc.
Via Business Wire
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
From Ambry Genetics
Via Business Wire
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
From Tempus AI, Inc.
Via Business Wire
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
From Tempus AI, Inc.
Via Business Wire
Tempus Reports First Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
From Tempus AI, Inc.
Via Business Wire
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
From FN Media Group LLC
Via GlobeNewswire
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
From Tempus AI, Inc.
Via Business Wire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
From Tempus AI, Inc.
Via Business Wire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
From Tempus AI, Inc.
Via Business Wire
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
Tempus to Report First Quarter 2025 Financial Results on May 6
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.